---

Recent Advances in Molecular Diagnostic Techniques

---

1. Next-Generation Sequencing (NGS)

What It Is

Recent Advances

• Panel testing: Simultaneous interrogation of dozens to hundreds of genes relevant to a phenotype (e.g., hereditary cancer panels, cardiomyopathy panels)
• Whole-exome sequencing (WES): Targets all coding exons (~1-2% of genome but contains ~85% of disease-causing variants)
• Whole-genome sequencing (WGS): 30x coverage gives comprehensive individual genomic evaluation; cost now below $500/genome
• RNA-seq: Transcriptome-level analysis, enabling fusion gene detection and expression profiling

• Oxford Nanopore Technology (ONT) and PacBio HiFi enable reads of 10,000-100,000+ bp (vs ~150 bp for short-read NGS)
• Better resolution of structural variants, repeat expansions, and phasing of alleles
• Real-time sequencing enables rapid clinical turnaround (results in hours, not days)

• AI-powered variant classification pipelines (ACMG guidelines automation)
• Multi-omics integration: combining genomics + transcriptomics + epigenomics data
• Cloud-based platforms enabling global data sharing

• Metagenomic NGS (mNGS) identifies any pathogen directly from clinical samples without prior culture - particularly transformative for unexplained encephalitis, immunocompromised infections, and pandemic surveillance (SARS-CoV-2 lineage tracking)

• Oncology: tumor mutational burden (TMB), microsatellite instability (MSI), somatic mutation profiling for targeted therapy selection
• Hereditary disease: constitutional WES/WGS now standard-of-care for pediatric rare disease
• Pharmacogenomics: NGS panels for CYP2D6, CYP2C19 polymorphisms guiding drug dosing
• Non-invasive prenatal testing (NIPT): cell-free fetal DNA sequencing from maternal blood

---

2. Liquid Biopsy

What It Is

Components

Recent Advances

• Cobas EGFR v2 test (FDA-approved) for EGFR mutation detection in NSCLC from plasma when tissue biopsy is insufficient
• Guardant360 CDx: FDA-approved comprehensive liquid biopsy panel (74 genes) as companion diagnostic for multiple targeted therapies
• FoundationOne Liquid CDx: FDA-approved pan-cancer blood-based NGS test

• Galleri test (GRAIL): Detects methylation signatures of ctDNA across 50+ cancer types from a single blood draw - represents a major clinical advance
• PATHFINDER trial demonstrated feasibility in screening populations
• Challenge: sensitivity drops for early-stage, localized cancers (Stage I sensitivity ~20-40% vs Stage IV >80%)

• Personalized ctDNA assays (e.g., clonoSEQ, Signatera) track molecular residual disease post-surgery/chemotherapy
• Predicts relapse months before clinical or radiologic evidence
• Validated in colorectal cancer, breast cancer, AML, lymphoma

• Serial liquid biopsies map clonal evolution and emergence of resistance mutations (e.g., T790M in EGFR-mutated NSCLC, C797S emergence after osimertinib)

• EU CANCER-ID and European Liquid Biopsy Society (ELBS) consortia have developed validated analytical platforms
• Preanalytical standardization (tube type, centrifugation, storage) is recognized as critical to reproducibility

• Sensitivity limitations in early-stage or low tumor-fraction samples
• Lack of large comparative trials vs tissue biopsy with defined survival endpoints
• Need for standardized preanalytical and analytical protocols across platforms

---

3. Companion Diagnostics (CDx)

What It Is

Recent Advances

• FDA, EMA, and other agencies have developed dedicated CDx pathways - over 50 FDA-approved CDx assays now exist (2024), predominantly in oncology
• Shift from single-gene assays to NGS-based panel CDx (e.g., FoundationOne CDx approved as CDx for 13+ drugs across multiple tumor types)
• "Agnostic" or tumor-agnostic approvals: CDx tests linked to drugs approved based on biomarker (MSI-H, NTRK fusion, TMB-H) rather than tumor type - a paradigm shift in precision oncology

• PD-L1 IHC (22C3, 28-8): CDx for pembrolizumab, nivolumab in multiple cancers
• EGFR mutation tests: CDx for erlotinib, osimertinib, gefitinib in NSCLC
• BRAF V600E tests: CDx for vemurafenib, dabrafenib in melanoma and colorectal cancer
• HER2 (FISH/IHC/NGS): CDx for trastuzumab, pertuzumab, trastuzumab deruxtecan
• RET, MET, KRAS G12C, FGFR: New CDx-drug pairs approved 2022-2025
• KRAS G12C (sotorasib, adagrasib): first KRAS-targeted therapy with CDx

• Imaging-based CDx: PET ligands (e.g., FAPI-PET, amyloid-PET) as companion diagnostics for radiopharmaceutical therapies
• Protein/phosphoprotein biomarkers
• Liquid biopsy CDx (plasma-based)

• Different drugs may require different validated CDx assays for the same biomarker (e.g., multiple PD-L1 assays with different cut-offs)
• International harmonization between FDA, EMA, and MFDS regulatory requirements is ongoing

---

4. Telepathology

What It Is

Modalities

1. Static - Photomicrographs selected and transmitted (low bandwidth, limited sampling)
2. Dynamic/live - Real-time streaming; remote pathologist "drives" a robotic microscope
3. Whole Slide Imaging (WSI) - Entire glass slide digitized at 20x or 40x; most transformative modality

Recent Advances

• Multiple WSI platforms (Philips IntelliSite, Leica Aperio AT2) received FDA 510(k) clearance for primary histopathologic diagnosis of formalin-fixed paraffin-embedded (FFPE) tissue
• Validated in multiple studies as non-inferior to conventional glass slide diagnosis for primary surgical pathology

• Deep learning algorithms (CNNs, Vision Transformers) achieve pathologist-level performance in:
  • Prostate cancer grading (Gleason scoring)
  • Lymph node metastasis detection in breast cancer
  • Colorectal cancer subtyping
  • Prediction of microsatellite instability from H&E slides alone
• FDA-cleared AI tools: Paige Prostate (first FDA-cleared AI for cancer detection in pathology), PathAI tools
• Foundation models (e.g., UNI, CONCH, PathChat): large pre-trained pathology models enabling few-shot learning across diverse tasks

• Intraoperative frozen section consultation via telepathology - enables specialist input for remote hospitals during surgery
• Tumor board support: instant digital sharing of slides globally
• Resource-limited settings: programs in Africa and Southeast Asia using smartphone-based telepathology for malaria, TB, cervical cancer screening
• Education and quality assurance: virtual slide sets replacing glass teaching collections

• Spatial transcriptomics overlaid on H&E images enables "morphomolecular" correlations
• H&E-based prediction of genomic features (EGFR, BRAF mutations) emerging

---

5. DNA and Tissue Microarrays

DNA Microarrays

• Array CGH / SNP arrays: Millions of oligonucleotide probes detect chromosomal copy number variants (CNVs) and loss of heterozygosity (LOH); has largely replaced conventional karyotyping for postnatal developmental delay workup
• Uniparental disomy (UPD) detection: SNP arrays uniquely detect UPD without copy number change - detects Prader-Willi, Angelman, Beckwith-Wiedemann syndromes
• Methylation arrays (Illumina 850K EPIC array): 850,000 CpG sites; now used for CNS tumor classification per WHO 2021 (methylation profiling outperforms histology for brain tumor subtyping)
• Expression microarrays: Gene expression profiling for cancer subtyping (PAM50 for breast cancer intrinsic subtypes - basis of Oncotype DX, Prosigna)
• Peptide microarrays: Detection of autoantibodies for autoimmune and infectious disease serology (COVID-19 antibody profiling, cancer neoantigen discovery)
• Aptamer/SELEX arrays: Novel non-antibody capture agents with superior stability
• MLPA (Multiplex Ligation-dependent Probe Amplification): Rapid copy number analysis for specific genomic regions without full array

Tissue Microarrays (TMA)

• High-throughput biomarker validation: Testing a new antibody or IHC protocol on 200+ cases simultaneously on a single TMA slide
• Automated image analysis: Digital pathology platforms now perform automated scoring of TMAs (H-score, Allred score) removing observer variability
• 3D TMAs: Sectioning at multiple levels to capture tumor heterogeneity
• RNA-scope/ISH on TMAs: Spatial gene expression in archived tissues
• Patient-derived organoid arrays: Emerging concept for functional drug testing

---

6. PCR

Recent Advances

• Partitions the reaction into thousands-to-millions of nanoliter droplets (ddPCR - droplet digital PCR) or chambers (crystal digital PCR)
• Each partition contains 0 or 1 template molecule - enables absolute quantification without reference standards
• Sensitivity: can detect 1 mutant molecule in 10,000 wild-type (0.01% allelic fraction)
• Applications: ctDNA quantification, MRD monitoring, rare mutation detection, CNV analysis, viral load quantification
• Recent clinical use: ctDNA monitoring post-surgery, transplant donor-derived cell-free DNA for rejection monitoring

• Combines isothermal amplification (RPA/LAMP) with CRISPR-Cas12/Cas13 for lateral flow or fluorescent readout
• Attomolar sensitivity, single-base discrimination
• Point-of-care (POC) format - paper-based, no cold chain, results in <1 hour
• FDA-authorized SARS-CoV-2 diagnostics based on this platform

• Panels testing 20+ respiratory pathogens simultaneously (BioFire FilmArray, GenMark ePlex)
• Meningitis/encephalitis panels, blood culture identification panels, GI pathogen panels - all FDA-cleared
• Turnaround: 1-2 hours vs 24-72 hours for culture

• No thermocycler needed - runs at 60-65°C
• POC deployment in low-resource settings (TB, malaria, neglected tropical diseases)
• COVID-19 rapid testing platforms widely deployed during pandemic

• Multiplexed gene expression profiling from specific regions of interest within FFPE tissue sections
• Enables "proteogenomics" at the tissue level

---

7. Biobanking

What It Is

Recent Advances

• UK Biobank (500,000 participants): Whole-genome sequencing of all participants completed (2023) - the largest WGS biobank globally
• All of Us Research Program (NIH, USA): 1 million+ participants; integrates EHR, genomics, wearable sensor data, social determinants of health
• FinnGen: 500,000 Finnish participants with national registry linkage; identified hundreds of novel disease-gene associations
• UAE Genome Programme, China Kadoorie Biobank: Major non-Western biobanks addressing population diversity gap

• Automated biobanking systems: Robotic sample storage and retrieval at -80°C or in liquid nitrogen with RFID tracking (Brooks Automation, Hamilton)
• Virtual biobanks: Federated data sharing - institutions maintain samples locally but share de-identified data globally (BBMRI-ERIC network in Europe)
• Long-term RNA stability: PAXgene tubes for blood RNA stabilization; Qiagen RNAlater for tissue RNA preservation enables transcriptomic studies from archival samples
• Organoid biobanks: Living patient-derived organoids (PDOs) from colorectal, pancreatic, breast cancers archived for drug sensitivity profiling

• Biobank data driving polygenic risk scores (PRS) for common diseases
• Pharmacogenomic studies on biobank cohorts informing drug repurposing
• Linking imaging biobanks (radiology + pathology WSI) with genomic data

• Dynamic consent platforms: Participants update their consent preferences digitally over time
• GDPR compliance frameworks for European biobanks
• Global Alliance for Genomics and Health (GA4GH) standards for federated data access

---

8. Microbiome

What It Is

Diagnostic Advances

• Sequences all DNA in a clinical sample, profiling both taxa and functional gene content
• Identifies unculturable organisms missed by 16S rRNA amplicon sequencing
• Clinical metagenomic sequencing for sepsis/infection (UCSF IDseq, Karius test) - FDA breakthrough designation for plasma metagenomic NGS for infectious disease

• Oncology: Intratumoral microbiome (bacteria within tumor cells) found in multiple cancers; gut microbiome composition predicts response to immune checkpoint inhibitors (ICI) - patients with Lachnospiraceae, Faecalibacterium prausnitzii-rich microbiomes show better anti-PD-1 responses
• Neurology: Gut-brain axis; gut microbiome alterations in Alzheimer's disease, Parkinson's, ALS - potential diagnostic biomarkers
• Cardiovascular: TMAO (trimethylamine N-oxide) production by gut bacteria linked to atherosclerosis; microbiome-based cardiovascular risk stratification emerging
• Metabolic disease: Microbiome signatures distinguish Type 2 diabetes, obesity; Akkermansia muciniphila abundance inversely correlates with metabolic syndrome

• FDA approved Rebyota (RBX2660) and Vowst (SER-109) in 2023 - first approved microbiome-based therapeutics for recurrent C. difficile infection
• Expanding into IBD, graft-vs-host disease (GVHD), oncology

• Cologuard (Exact Sciences): stool DNA + microbiome markers for colorectal cancer screening (FDA approved)
• Microbiome-based IVD tests for IBD activity, pouchitis in development
• Virome profiling (identifying gut viral communities) - emerging frontier

• DNA extraction method, 16S vs shotgun, reference database choice all affect community profiles
• No universal reference microbiome standard exists yet

---

9. Limitations of Molecular Diagnostic Techniques

Analytical Limitations

Technical Limitations

• Long-read sequencing: Higher error rate per read (though improved with HiFi chemistry); higher cost per base than short-read
• WGS/WES: Fails to sequence ~10-15% of the genome (repetitive regions, GC-rich regions, structural variant breakpoints)
• NGS bioinformatics: No universal variant calling pipeline - different tools produce different results from the same raw data; reference genome bias against non-European populations
• Array CGH: Cannot detect balanced chromosomal rearrangements (translocations, inversions) - conventional karyotype still needed
• Microbiome: No universally accepted reference database; compositional data nature requires specialized statistical methods

Clinical/Interpretive Limitations

• Variants of uncertain significance (VUS): Major challenge in returning results - ethically complex, no clear management pathway
• Incidental/secondary findings: WGS/WES reveals findings unrelated to the primary indication (e.g., hereditary cancer syndrome found during cardiac gene panel)
• Actionability gap: Many identified mutations have no matched therapy; therapeutic implications of many somatic variants remain unknown
• Result turnaround: Comprehensive NGS panels may take 2-4 weeks, limiting utility in acute clinical settings (though rapid WGS turnaround in <24 hours is now achieved in select centers for critically ill neonates)
• Clinical interpretation training: Molecular pathology requires specialized expertise - shortage of trained molecular pathologists and genetic counselors

Cost, Access, and Equity

• Comprehensive NGS and liquid biopsy tests cost $1,000-$10,000+ per test; reimbursement coverage is inconsistent
• Digital pathology/WSI requires significant infrastructure investment
• Biobank and microbiome research overrepresented by European/North American populations - poor diversity limits applicability of polygenic risk scores and microbiome normative ranges to other populations
• Low-resource settings lack cold chain infrastructure for biobanking and NGS

Regulatory and Ethical Limitations

• Data storage and privacy: WGS generates ~100 GB per genome; long-term storage, security, and re-identification risk
• Liquid biopsy standardization: No universal pre-analytical standard; results not comparable across platforms
• Companion diagnostic concordance: Different CDx assays for the same biomarker (e.g., PD-L1) use different scoring cut-offs leading to discordant results
• Dynamic consent and secondary use of biobank data: ongoing ethical debates about re-contacting donors, commercial partnerships

---

Summary Table